Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced that Howard Schiller has been appointed interim chief executive officer, effective immediately. The company said Michael Pearson remains in the hospital where he is being treated for severe pneumonia, and as the timing of his expected return is uncertain, he will be on a medical leave of absence until further notice.
Schiller served as Valeant's CFO from December 2011 through June 2015 and currently serves on Valeant's Board.
Valeant also announced that Robert Ingram, Lead Independent Director, will serve as interim chairman of the Board.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.